Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
NCT06192797Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Tongji Hospital. Started Jun 2024; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06192797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192797.